Some NSAIDs, particularly sulindac (Clinoril) and diclofenac
, showed higher rates of hepatic injury and
transaminase elevation more than three times the upper limit of normal compared with placebo. However, even in large systematic reviews, clinically significant outcomes, such as hospitalization or death, were rare. NSAIDs do carry some risk in persons with impaired hepatic function.